Investment Snapshot

Mission Statement

A clinical-stage biotechnology company creating cancer immunotherapies that enlist the body’s own immune system to fight cancer.

Advaxis’ proprietary Lm targeted immunotherapy is a new approach toward an effective cancer vaccine.

Our Lm Technology has achieved safety and efficacy endpoints in early-stage trials and is the platform for our continued focus on the science, discovery, development and commercialization of cutting-edge cancer treatments.

Investment Snapshot

Flexible Platform Technology

  • Platform based on attenuated Lm (Listeria Monocytogenes)
  • Multiple approaches to impacting the immune system
  • Manageable safety profile: common AEs are mostly mild to moderate and resolve within 48 hours

Broad Pipeline

  • Clinical stage programs: HPV-Associated Cancers, Prostate Cancer, ADXS-NEO and ADXS-HOT

Ability to combine with other I-O agents

  • Demonstrated preclinical synergy with multiple checkpoint inhibitors and co-stimulatory agents
  • Three clinical trials in combination with PD-1/PDL-1 inhibitors

Experienced Management Team

  • Deep and broad experience in pharmaceutical drug development and commercialization
Business Wire InvestorHQsm